Osiris Hiccup In COPD Barely Registers In Maturing Stem Cell Sector
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The rapidly evolving stem cell space may have matured to the level where a single company’s misstep no longer raises questions about the viability of the whole endeavor. At least that seems to be the reaction following Osiris Therapeutics’ recent announcement that its mesenchymal stem cell therapy Prochymal produced mixed results in an interim look at a study of 62 patients with chronic obstructive pulmonary disease.
You may also be interested in...
Osiris Will Focus On Liver GvHD While Sorting Data From Failed Studies
"The idea of giving up and going home is simply not in the cards," CEO Mills says.
Osiris/Genzyme Anticipates Approval Of Stem Cell Therapy Prochymal By 2010
Osiris begins the FDA submission process for its mesenchymal stem cell therapy Prochymal this quarter, making a late-2009 approval of the world's first stem cell therapy a possibility if the agency grants a six-month review, and a first-cycle approval
Geron Gets Green Light To Test Embryonic Stem Cell Therapy On Humans
After being delayed since May, Geron’s 21,000-page application clears overnight in the first week of the Obama administration.